Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC

Rafael Rosell¹, Niki Karachaliou², Carles Codony-Servat³, Masaoki Ito^{1

3

4}

Affiliations

¹ Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain.
² Instituto Oncológico Rosell (IOR), Hospital Sagrat Cor, Quironsalud, Barcelona, Spain.
³ Pangaea Oncology, Barcelona, Spain.
⁴ Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

Editorial

Rafael Rosell et al. Transl Lung Cancer Res. 2018 Sep.

. 2018 Sep;7(Suppl 3):S183-S186.

doi: 10.21037/tlcr.2018.03.20.

Rafael Rosell¹, Niki Karachaliou², Carles Codony-Servat³, Masaoki Ito^{1

3

4}

¹ Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain.
² Instituto Oncológico Rosell (IOR), Hospital Sagrat Cor, Quironsalud, Barcelona, Spain.
³ Pangaea Oncology, Barcelona, Spain.
⁴ Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Jänne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crinò L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J. Jänne PA, et al. JAMA. 2017 May 9;317(18):1844-1853. doi: 10.1001/jama.2017.3438. JAMA. 2017. PMID: 28492898 Free PMC article. Clinical Trial.

1. Kim J, McMillan E, Kim HS, et al. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature 2016;538:114-7. 10.1038/nature19771 - DOI - PMC - PubMed
1. Karachaliou N, Mayo C, Costa C, et al. KRAS mutations in lung cancer. Clin Lung Cancer 2013;14:205-14. 10.1016/j.cllc.2012.09.007 - DOI - PubMed
1. Rosell R, Gonzalez-Larriba JL, Alberola V, et al. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Semin Oncol 1995;22:12-8. - PubMed
1. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12. 10.1038/nature08460 - DOI - PMC - PubMed
1. Jänne PA, van den Heuvel MM, Barlesi F, et al. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. JAMA 2017;317:1844-53. 10.1001/jama.2017.3438 - DOI - PMC - PubMed